Abstract
A large number of therapeutic roles have been proposed for σ1 receptors but the involvement of σ1 receptor in non-acute pain had not been well explored up to now. σ1 receptor knock-out mice became available offering us the possibility to study the role of σ1 receptor in nociception, particularly in models where central sensitization processes play a significant role. Given the attractive therapeutic potential, we have developed a chemical program aimed at the discovery of novel and selective σ1 ligands. Herein we discuss the rational basis of this approach and report preliminary pharmacological results of several chemical series and aspects of their structure-activity relationship on σ1 receptor. Functional data in pain models are presented mainly on one series that provide evidence to consider selective σ1 receptor antagonists an innovative and alternative approach for treating neuropathic pain.
Keywords: Neuropathic pain, analgesia, sigma-1 antagonists, sigma-1 knock-out, central sensitization
Central Nervous System Agents in Medicinal Chemistry
Title: Selective Sigma-1 (σ1) Receptor Antagonists: Emerging Target for the Treatment of Neuropathic Pain
Volume: 9 Issue: 3
Author(s): Jose Luis Diaz, Daniel Zamanillo, Jordi Corbera, Jose Manuel Baeyens, Rafael Maldonado, Miquel Angel Pericàs, Jose Miguel Vela and Antoni Torrens
Affiliation:
Keywords: Neuropathic pain, analgesia, sigma-1 antagonists, sigma-1 knock-out, central sensitization
Abstract: A large number of therapeutic roles have been proposed for σ1 receptors but the involvement of σ1 receptor in non-acute pain had not been well explored up to now. σ1 receptor knock-out mice became available offering us the possibility to study the role of σ1 receptor in nociception, particularly in models where central sensitization processes play a significant role. Given the attractive therapeutic potential, we have developed a chemical program aimed at the discovery of novel and selective σ1 ligands. Herein we discuss the rational basis of this approach and report preliminary pharmacological results of several chemical series and aspects of their structure-activity relationship on σ1 receptor. Functional data in pain models are presented mainly on one series that provide evidence to consider selective σ1 receptor antagonists an innovative and alternative approach for treating neuropathic pain.
Export Options
About this article
Cite this article as:
Diaz Luis Jose, Zamanillo Daniel, Corbera Jordi, Baeyens Manuel Jose, Maldonado Rafael, Pericàs Angel Miquel, Vela Miguel Jose and Torrens Antoni, Selective Sigma-1 (σ1) Receptor Antagonists: Emerging Target for the Treatment of Neuropathic Pain, Central Nervous System Agents in Medicinal Chemistry 2009; 9 (3) . https://dx.doi.org/10.2174/1871524910909030172
DOI https://dx.doi.org/10.2174/1871524910909030172 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Discovery of <i>Channa Striata</i> Extracts as Regenerative Medicine in Promoting Wound Healing and Scarless Skin Regeneration
The Natural Products Journal Vaccine Development for Alzheimers Disease
Current Pharmaceutical Design Computer Simulations of the Retinoid X Receptor: Conformational Dynamics and Allosteric Networks
Current Topics in Medicinal Chemistry Retrograde Modulation of Synaptic Transmission Mediated by Endogenous Cannabinoids
Current Neuropharmacology Meet Our Editorial Board Member
Current Medical Imaging Editorial [Hot Topic: Comparative Biochemistry of Molecular Targets for Drug and Pesticides: N-Acetyl-D-glucosamine and Acetylcholine Related Enzymes (Guest Editor: Qing Yang )]
Current Drug Targets Muscular Gene Transfer Using Nonviral Vectors
Current Gene Therapy Formulation and Characterization of Mucoadhesive Microparticles of Cinnarizine Hydrochloride Using Supercritical Fluid Technique
Current Drug Delivery Clinical Relevance of Apolipoprotein E Genotyping Based on a Family History of Alzheimer's Disease
Current Alzheimer Research Biological and In silico Studies on Synthetic Analogues of Tyrosine Betaine as Inhibitors of Neprilysin - A Drug Target for the Treatment of Heart Failure
Current Pharmaceutical Design Long-Range Contacts in Unfolding of Two-State Proteins
Protein & Peptide Letters A Study on the Mechanism of Lavender in the Treatment of Insomnia Based on Network Pharmacology
Combinatorial Chemistry & High Throughput Screening Synthesis and Preliminary Biological Evaluation of New Heterocyclic Carboxamide Models
Letters in Drug Design & Discovery Development of Biodegradable Glimepiride Loaded Chitosan Nano Particles: A Factorial Design Approach
Current Environmental Engineering Multifunctional Nature of Human Retinol Dehydrogenases
Current Organic Chemistry Improvement of the Mechanical and Thermal Properties of Bayfol CR6-2 Polymer using UV Radiation
Recent Patents on Mechanical Engineering Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Structure-Activity Relationships of Glutamate Carboxypeptidase II (GCPII) Inhibitors
Current Medicinal Chemistry The Role of Platelets and their Microparticles in Rehabilitation of Ischemic Brain Tissue
CNS & Neurological Disorders - Drug Targets Evaluating a Child with Partial Developmental Delay (ParDD), Global Developmental Delay (GDD)/Mental Retardation (MR): Clinical Expertise Based or Evidence-Based?
Current Pediatric Reviews